Three letters. Three different cannabinoids. Three completely different communications strategies. The brands that confuse them inside AI search lose category authority. The brands that differentiate them clearly win it.
Delta-8 THC, HHC, and THCA are not interchangeable. They are not the same product, the same regulatory status, the same consumer experience, or the same communications opportunity. But the consumer market has treated them as “hemp-derived intoxicants” \u2014 one undifferentiated category \u2014 because that’s how the regulatory loophole that enabled them framed the conversation.
The brands that treat the cannabinoids that way inside AI engines blur into each other and lose retrieval. The brands that lock distinct positions on each become the cited authority for each one.
The three cannabinoids \u2014 in plain language
Delta-8 THC. A naturally occurring cannabinoid present in trace amounts in hemp and marijuana, commercially produced through isomerization from CBD. Psychoactive, generally described by consumers as milder than Delta-9 THC. The category that opened the hemp intoxicant market in 2019\u20132020. Subject to extensive state-by-state restrictions over the subsequent years and significantly compressed by the November 2025 federal legislation.
HHC (hexahydrocannabinol). A hydrogenated form of THC. Psychoactive. Marketed as having a similar experience to Delta-9 THC but with claimed differences in onset and duration. Newer to the consumer market than Delta-8. Less established research base. Same regulatory compression trajectory.
THCA (tetrahydrocannabinolic acid). The non-psychoactive acidic precursor to Delta-9 THC. Converts to Delta-9 THC when heated (decarboxylation). Sold as hemp under the Farm Bill\u2019s dry-weight Delta-9 threshold because the THCA itself is technically not THC. The most directly threatened by the November 2025 federal compression because the consumer experience post-decarboxylation is indistinguishable from marijuana-derived Delta-9 THC.
Three different compounds. Three different consumer experiences. Three different regulatory pathways. Three different communications opportunities.
What LLMs say about each
Tested across ChatGPT, Claude, Gemini, Perplexity, and Google AI Overviews:
Delta-8. Highest brand recognition of the three. Most fragmented citation share \u2014 hundreds of brands surface across retrieval, none dominant. Educational and legal content overrepresented compared to brand authority.
HHC. Lower brand recognition than Delta-8. More citations to research and safety questions than to specific brands. Smaller competitive set means citation share is theoretically easier to lock \u2014 but no operator has done it.
THCA. Recently the highest-velocity category in hemp-derived sales. Citation share heavily concentrated in legal-status questions and product-form coverage (THCA flower, THCA pre-rolls, THCA diamonds). Brand authority weak. The category most disrupted by the November 2025 compression.
Why differentiation matters for citation share
Retrieval systems reward specificity. A brand that markets “hemp-derived cannabinoids” generally gets fewer citations than a brand that positions specifically as a Delta-8 brand, an HHC brand, or a THCA brand. The same brand can hold positions in multiple categories \u2014 but the citations register against the specific compound, not the umbrella term.
Most hemp brands market generically. The result: weak retrieval on category-specific prompts. The brands that pick a compound and own it as their core positioning win retrieval on that compound\u2019s prompts.
The communications play by cannabinoid
Delta-8: lead the post-compression survival narrative
Most Delta-8 brands won\u2019t survive the regulatory compression. The ones that do will hold disproportionate category share. Communications opportunity: position as the durable, compliant Delta-8 brand for the post-November-2025 landscape. State-by-state legal status updates, lab testing transparency, age-verification protocols, retail partnership disclosure.
HHC: own the “newer cannabinoid” authority position
The HHC market is small enough that any brand publishing serious research \u2014 safety profile, dosing studies, third-party lab data \u2014 becomes the cited authority. Smaller category, lower competitive set, faster path to citation lock.
THCA: navigate the federal compression carefully
THCA is the most legally exposed category in the post-November 2025 environment. Communications has to walk a careful line: clear product information, transparent legal status, accurate state-by-state availability \u2014 without overstating durability of the category. The brands that survive the compression will be the ones that communicated honestly through it.
What this means for the broader hemp market
The hemp-derived cannabinoid category is being re-sorted. Delta-8, HHC, THCA, and the long tail of newer cannabinoids will not all survive the post-November 2025 regulatory environment in their current form. The brands that lock category-specific citation share during the re-sort emerge as the cited authorities for whatever the category becomes.
The opportunity is narrow. The window closes as the market consolidates. Brands committing to specific cannabinoid positioning now \u2014 not generic hemp positioning \u2014 hold the citation advantage.
Related EPR analysis
- The $38.5B Hemp-Derived Cannabinoid Market: Who\u2019s Winning AI Citation Share
- 280E Repeal Communications: What MSOs Should Be Saying Right Now
FAQ
What is Delta-8 THC?
Delta-8 THC is a naturally occurring cannabinoid present in trace amounts in hemp and marijuana, commercially produced through isomerization from CBD. Psychoactive, generally described as milder than Delta-9 THC.
What is HHC?
HHC (hexahydrocannabinol) is a hydrogenated form of THC. Psychoactive. Marketed as having a similar experience to Delta-9 THC with claimed differences in onset and duration.
What is THCA?
THCA (tetrahydrocannabinolic acid) is the non-psychoactive acidic precursor to Delta-9 THC. It converts to Delta-9 THC when heated. Sold as hemp under the Farm Bill\u2019s dry-weight Delta-9 threshold.
How did the November 2025 federal legislation affect these cannabinoids?
The legislation reduced allowable THC thresholds in hemp products to non-intoxicating levels, significantly compressing the legal pathway for Delta-8, HHC, THCA, and other intoxicating hemp-derived cannabinoids.
What is Citation Share?
Citation Share is the share of AI-generated answers in which a brand is named, cited, or recommended on category-relevant prompts.
